Beyond Air has published a new US patent application detailing methods for inhibiting tumor growth using gaseous nitric oxide. This development signals potential expansion into oncology, which could open new revenue streams if successful, but is a very early-stage development.
Beyond Air (XAIR) has published a new US patent application (US-20260284331-A1) related to the use of gaseous nitric oxide for inhibiting tumor growth. This is a positive development for the company as it indicates potential expansion of its technology into the oncology space, a large and lucrative market. While a patent application is a very early stage and does not guarantee commercial success or even approval, it signals the company's strategic direction and potential for future product development. For traders, this presents a long-term opportunity if the research progresses, but short-term impact is likely limited given the early stage. The key risk is that the research may not yield viable products or face significant regulatory hurdles.